Wyeth receives "approvable" letter for Effexor (venlafaxine) for new indication of prevention of depression relapse and remission. "FDA has accepted the basic data [and] it's now a question of discussion of the final labeling," AHP VP-Investor Relations Justin Victoria says. "Those discussions are underway." The sNDA was filed in May 2000. Effexor, indicated for depression, anxiety and narcotic overdose, generated $208 mil. in U.S. sales in the first quarter, up 14.4%
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth